Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

The Lancet Oncology

Volumn 13, Issue 1, 2012, Pages 100-110

  Wheeler, Cosette M ^a   Castellsagué, Xavier ^b   Garland, Suzanne M ^c   Szarewski, Anne ^d   Paavonen, Jorma ^e   Naud, Paulo ^f   Salmerón, Jorge ^g   Chow, Song Nan ^h   Apter, Dan ⁱ   Kitchener, Henry ^j   Teixeira, Júlio C ^k   Skinner, S Rachel ^l,x   Jaisamrarn, Unnop ^m   Limson, Genara ⁿ   Romanowski, Barbara ^o   Aoki, Fred Y ^p   Schwarz, Tino F ^q   Poppe, Willy A J ^r   Bosch, F Xavier ^b   Harper, Diane M ^s   Huh, Warner ^t   Hardt, Karin ^u   Zahaf, Toufik ^u   Descamps, Dominique ^u   Struyf, Frank ^u   Dubin, Gary ^v   Lehtinen, Matti ^w   more..

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY OF HELSINKI   (Finland)

^f HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^g INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^h NATIONAL TAIWAN UNIVERSITY   (Taiwan)

ⁱ Vaestoliitto   (Finland)

^j UNIVERSITY OF MANCHESTER   (United Kingdom)

^k UNIVERSITY OF CAMPINAS   (Brazil)

^l UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^m CHULALONGKORN UNIVERSITY   (Thailand)

ⁿ UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^o UNIVERSITY OF ALBERTA   (Canada)

^p UNIVERSITY OF MANITOBA   (Canada)

^q UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^r UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^s DARTMOUTH MEDICAL SCHOOL   (United States)

^t UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^u GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^v GLAXOSMITHKLINE   (United States)

^w UNIVERSITY OF TAMPERE   (Finland)

^x UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE; VIRUS DNA; WART VIRUS VACCINE;

ADULT; ARTICLE; CANCER GRADING; CANCER PREVENTION; COHORT ANALYSIS; CONTROLLED STUDY; CROSS PROTECTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; INFECTION PREVENTION; MIXED INFECTION; NORMAL HUMAN; PAPILLOMAVIRUS INFECTION; PERSISTENT INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUALITY; UTERINE CERVICITIS; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS TYPING; WART VIRUS;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ALUMINUM HYDROXIDE; ANTIGENS, VIRAL; ASIA; AUSTRALIA; CERVICAL INTRAEPITHELIAL NEOPLASIA; CROSS REACTIONS; DNA, VIRAL; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; LIPID A; NEOPLASM GRADING; NORTH AMERICA; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRECANCEROUS CONDITIONS; SOUTH AMERICA; TIME FACTORS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84855309413     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70287-X     Document Type: Article

References (39)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
2. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.
3. de Sanjosé S, Quint WGV, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11:1048-1056. on behalf of the Retrospective International Survery and HPV Time Trends Study Group.
4. Schiffman M, Clifford G, Buonaguro FM Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009, 4:8.
5. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011, 128:927-935.
6. Bishop B, Dasgupta J, Klein M, et al. Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies. J Biol Chem 2007, 282:31803-31811.
7. Ryding J, Dahlberg L, Wallen-Ohman M, Dillner J Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles. J Gen Virol 2007, 88:792-802.
8. Chen Z, DeSalle R, Schiffman M, Herrero R, Burk RD Evolutionary dynamics of variant genomes of human papillomavirus types 18, 45, and 97. J Virol 2009, 83:1443-1455.
9. Smith JF, Brownlow M, Brown M, et al. Antibodies from women immunized with Gardasil cross-neutralize HPV-45 pseudovirions. Hum Vaccin 2007, 3:109-116.
10. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007, 369:2161-2170. for the HPV PATRICIA Study Group.
11. Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314. for the HPV PATRICIA Study Group.
12. Muñoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010, 102:325-339.
13. Hildesheim A, Schiffman MH, Gravitt ME, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994, 169:235-240.
14. Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995, 87:1365-1371.
15. Koshiol J, Lindsey L, Pimenta JM, Poole C, Jenkins D, Smith JS Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008, 168:123-137.
16. Kjær SK, Frederiksen K, Munk C, Iftner T Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010, 102:1478-1488.
17. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2011, for the HPV PATRICIA Study Group, published online Nov 9. 10.1016/S1470-2045(11)70286-8.
18. Lehtinen M, Apter D, Dubin G, et al. Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing. Int J STD AIDS 2006, 17:517-521.
19. van Doorn L-J, Molijn A, Kleter B, Quint W, Colau B Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol 2006, 44:3292-3298.
20. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens-Part B: biological agents. Lancet Oncol 2009, 10:321-322.
21. Quint W, Molijn A, Guimera N, et al. Which HPV type caused that lesion? The value of the laser capture microscopy technology. HPV Today 2011, 23:8-9.
22. Clifford GM, Smith JS, Aguado T, Franceschi S Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003, 89:101-105.
23. Schiffman M, Herrero R, DeSalle R, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005, 337:76-84.
24. Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WGV, Castle PE Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009, 101:475-487.
25. Vinokurova S, Wentzensen N, Kraus I, et al. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res 2008, 68:307-313.
26. Wheeler CM, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009, 199:936-944.
27. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009, 199:926-935.
28. Bulkmans NW, Bleeker MCG, Berkhof J, Voorhorst FJ, Snijders PJF, Meijer CJLM Prevalence of types 16 and 33 is increased in high-risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse. Int J Cancer 2005, 117:177-191.
29. Insinga RP, Perez G, Wheeler CM, et al. Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev 2011, 20:287-296. FUTURE I Investigators.
30. Smith HO, Tiffany MF, Qualls CR, Key CR The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States-a 24-year population-based study. Gynecol Oncol 2000, 78:97-105.
31. Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008, 26:1-16.
32. Wentzensen N, Schiffman M, Dunn ST, et al. Multiple HPV genotype infections in cervical cancer progression in the Study to Understand Cervical Cancer Early Endpoints and Determinants (SUCCEED). Int J Cancer 2009, 125:2151-2158.
33. Zuna RE, Allen RA, Moore WE, Lu Y, Mattu R, Dunn ST Distribution of HPV genotypes in 282 women with cervical lesions: evidence for three categories of intraepithelial lesions based on morphology and HPV type. Mod Pathol 2007, 20:167-174.
34. Herrero R, Hildesheim A, Rodriguez AC, et al. Rationale and design of a community-based double-blind clinical trial of an HPV-16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine 2008, 26:4795-4808.
35. Kemp T, Hildesheim A, Safaeian M, et al. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 2011, 29:2011-2014.
36. Giroglou T, Sapp M, Lane C, et al. Immunological analyses of human papillomavirus capsids. Vaccine 2001, 19:1783-1793.
37. Combita AL, Touzé A, Bousarghin L, Christensen ND, Coursaget P Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol 2002, 76:6480-6486.
38. Roth SD, Sapp M, Streeck RE, Selinka HC Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33. Virology J 2006, 3:83.
39. Fleury MJ, Touzé A, Maurel MC, Moreau T, Coursaget P Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications. Protein Sci 2009, 18:1425-1438.